HIF-1α Translation Inhibitor, KC7F2-CAS 927822-86-4-Calbiochem

C₁₆H₁₆Cl₄N₂O₄S₄

570.38

MFCD22683809

A cell-permeable symmetrical cystamine compound that selectively suppresses cellular HIF-1α, but not HIF-1β, protein synthesis without affecting the transcription of HIF-1α mRNA or the stability of HIF-1α protein. Reduction of cellular HIF-1α by KC7F2 treatment (IC₅₀<20 µM in LN229 cultures under hypoxia condition) is shown to result in decreased transcriptions of HIF-1α-dependent genes, such as CA IX, endothelin 1, enolase 1, and MMP-2. Inhibition of 4EBP1 and S6K phosphorylation, important event for the initiation of protein translation, is also observed in KC7F2 and U87MGD cultures following KC7F2 treatment under hypoxia condition, which may account for, at least in part, the downregulated HIF-1α synthesis.

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Narita, T., et al. 2009. Clin. Cancer Res.15, 6128.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥95% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

beige to tan

DMSO: 100 mg/mL

ambient

−20℃

25 mg in Plastic ampoule
Packaged under inert gas

11 - Combustible Solids

WGK 3